Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, the Netherlands.
Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, the Netherlands; Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, the Netherlands.
Bone. 2022 Dec;165:116564. doi: 10.1016/j.bone.2022.116564. Epub 2022 Sep 21.
Studies on mice have shown a relationship between dietary intake of advanced glycation end-products (dAGEs) and deterioration of musculoskeletal health, but human studies are absent. We investigated the relationship between dietary intake of carboxymethyllysine (dCML) - an AGE prototype - and risk of sarcopenia at baseline and after 5 years of follow-up and a single evaluation of physical frailty in participants from the population-based Rotterdam Study. Appendicular lean mass (ALM) was obtained using insight dual-energy X-ray absorptiometry and hand grip strength (HGS) using a hydraulic hand dynamometer. Subjects with both low ALM and weak HGS were classified as having sarcopenia. Frailty (yes/no) was defined by presence of ≥3 and pre-frailty by presence of 1 or 2 components namely, exhaustion, weakness, slowness, weight loss or low physical activity. dCML was calculated using a food frequency questionnaire and dAGE databases. Logistic regression analysis was used to evaluate the odds of physical frailty and prevalent sarcopenia at baseline and follow-up and incident sarcopenia. 2782 participants with an age 66.4 ± 9.9 years and dCML intake 3.3 ± 1.3 mg/day, had data on sarcopenia at both time points. Of whom 84 had sarcopenia at baseline and 73 developed sarcopenia at follow-up. We observed an association of one SD increase in dCML intake with prevalent sarcopenia at baseline [odds ratio, OR = 1.27 (1.01-1.59)] and no association of dCML with incident sarcopenia at 5-year follow-up [OR = 1.12 (0.86-1.44)]. For frailty we analyzed 3577 participants, of whom 1972 were pre-frail and 158 were frail. We observed no association of dCML with either pre-frailty [OR = 0.99 (0.91-1.07)] or frailty [OR = 1.01 (0.83-1.22)] when non-frail subjects were used as reference. Our results show an association of dAGEs with sarcopenia cross-sectionally but not longitudinally where inconclusive findings are observed possibly due to a very low incidence of sarcopenia. There was no association with frailty cross-sectionally.
对老鼠的研究表明，饮食中晚期糖基化终产物（dAGEs）的摄入量与肌肉骨骼健康恶化之间存在关系，但目前还没有人类研究。我们调查了饮食中羧甲基赖氨酸（dCML） - AGE 原型 - 的摄入量与基线时和 5 年后随访时肌少症风险之间的关系，并在人群基础的鹿特丹研究中对参与者进行了身体虚弱的单次评估。使用 Insight 双能 X 射线吸收仪获得四肢瘦体重（ALM），使用液压手动测力计获得握力（HGS）。同时具有低 ALM 和弱 HGS 的受试者被归类为患有肌少症。（是/否）虚弱定义为存在≥3 个，衰弱前期定义为存在 1 或 2 个组成部分，即疲倦、虚弱、缓慢、体重减轻或体力活动低。dCML 使用食物频率问卷计算，dAGE 数据库。使用逻辑回归分析评估基线和随访时以及新发肌少症时身体虚弱和普遍肌少症的几率。2782 名年龄 66.4±9.9 岁，dCML 摄入量 3.3±1.3mg/天的参与者，在两个时间点都有肌少症的数据。其中 84 人基线时患有肌少症，73 人随访时患有肌少症。我们观察到 dCML 摄入量增加一个标准差与基线时普遍存在的肌少症相关[比值比，OR=1.27（1.01-1.59）]，而与 5 年随访时的新发肌少症无关[OR=1.12（0.86-1.44）]。对于虚弱，我们分析了 3577 名参与者，其中 1972 名处于衰弱前期，158 名处于衰弱状态。我们观察到 dCML 与衰弱前期[OR=0.99（0.91-1.07）]或衰弱[OR=1.01（0.83-1.22）]均无关联，当非虚弱组作为参考时。我们的结果显示，dAGEs 与肌少症存在横断面关联，但与纵向关联不相关，这可能是由于肌少症的发病率非常低。与虚弱无横断面关联。
